Significance of the Vascular Concentration of Angiotensin II–Receptor Blockers on the Mechanism of Lowering Blood Pressure in Spontaneously Hypertensive Rats
Authors:
Open Access
- 1 January 2013
- journal article
- Published by Japanese Pharmacological Society in Journal of Pharmacological Sciences
- Vol. 123 (4) , 371-379
Abstract
To clarify the hypotensive mechanism of angiotensin II receptor–blockers (ARBs), drug concentrations in plasma and vascular tissues were measured using matrix-assisted laser desorption ionization time-of-flight mass spectrometry and imaging mass spectrometry. In spontaneously hypertensive rats, systolic blood pressure (SBP) was measured 2 and 24 h after administration of candesartan cilexetil (0.3, 1, or 3 mg/kg) or azilsartan (0.3, 1, or 3 mg/kg). SBP was similarly lowered 2 h after administration of azilsartan or candesartan cilexetil, but it was significantly lower in the azilsartan-treated group than in the candesartan cilexetil-treated group at 24 h. Angiotensin II–induced vascular contractions were similarly attenuated 2 h after administration of these drugs, and the contractions were significantly lower in the azilsartan-treated group at 24 h. Although plasma concentration was significantly lower in the azilsartan-treated group at 24 h, vascular concentration of azilsartan was significantly greater than that of candesartan. Significant correlations between SBP and vascular concentrations were observed both at 2 and 24 h, while no significant correlation was observed between plasma and vascular concentrations. In conclusion, the mechanism of ARB-induced hypotension is likely to depend on vascular concentrations rather than plasma concentrations.Keywords
This publication has 20 references indexed in Scilit:
- 2013 ESH/ESC Guidelines for the management of arterial hypertensionJournal Of Hypertension, 2013
- Proposal of a new strategy for ambulatory blood pressure profile-based management of resistant hypertension in the era of renal denervationHypertension Research, 2013
- Erratum: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)—Chapter 2Hypertension Research, 2009
- Enhancement of protein sensitivity for MALDI imaging mass spectrometry after chemical treatment of tissue sectionsJournal of the American Society for Mass Spectrometry, 2008
- Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary PreventionStroke, 2005
- Significance of Angiotensin II Receptor Blocker Lipophilicities and Their Protective Effect against Vascular RemodelingHypertension Research, 2005
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 2002
- Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)The Lancet, 2000
- PATHOGENETIC ROLE OF VASCULAR ANGIOTENSIN-CONVERTING ENZYME IN THE SPONTANEOUSLY HYPERTENSIVE RATClinical and Experimental Pharmacology and Physiology, 1991